All In Biotech

Drug Trial Radar · NCT05203341

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

183

Actual

Start

Feb 21, 2022

Primary completion

Jan 10, 2024

Study completion Feb 21, 2024

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.

Conditions

  • Major Depressive Disorder

Interventions

  • PlaceboDrug

    Matching placebo tablets

  • NBI-1065845Drug

    NBI-1065845 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Montgomery Åsberg Depression Rating Scale (MADRS) Score at Day 28Time frame: Baseline, Day 28

Locations

41 sites in 6 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Birmingham, Alabama

  • Neurocrine Clinical Site

    Huntsville, Alabama

  • Neurocrine Clinical Site

    Riverside, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    San Francisco, California

  • Neurocrine Clinical Site

    Torrance, California

  • Neurocrine Clinical Site

    Hartford, Connecticut

  • Neurocrine Clinical Site

    Palmetto Bay, Florida

  • Neurocrine Clinical Site

    Gaithersburg, Maryland

  • Neurocrine Clinical Site

    Weldon Spring, Missouri

  • Neurocrine Clinical Site

    Columbus, Ohio

  • Neurocrine Clinical Site

    North Canton, Ohio

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma

  • Neurocrine Clinical Site

    Memphis, Tennessee

  • Neurocrine Clinical Site

    Dallas, Texas

  • Neurocrine Clinical Site

    Houston, Texas

  • Neurocrine Clinical Site

    Draper, Utah

  • Neurocrine Clinical Site

    Plovdiv, Bulgaria

  • Neurocrine Clinical Site

    Rousse, Bulgaria

  • Neurocrine Clinical Site

    Sofia, Bulgaria

  • Neurocrine Clinical Site

    Tsarev Brod, Bulgaria

  • Neurocrine Clinical Site

    Varna, Bulgaria

  • Neurocrine Clinical Site

    Veliko Tarnovo, Bulgaria

  • Neurocrine Clinical Site

    Vratsa, Bulgaria

  • Neurocrine Clinical Site

    Kladno, Czechia

  • Neurocrine Clinical Site

    Pilsen, Czechia

  • Neurocrine Clinical Site

    Prague, Czechia

  • Neurocrine Clinical Site

    Prague, Czechia

  • Neurocrine Clinical Site

    Prague, Czechia

  • Neurocrine Clinical Site

    Bełchatów, Poland

  • Neurocrine Clinical Site

    Chełmno, Poland

  • Neurocrine Clinical Site

    Gdansk, Poland

  • Neurocrine Clinical Site

    Katowice, Poland

  • Neurocrine Clinical Site

    Košice, Slovakia

  • Neurocrine Clinical Site

    Rimavská Sobota, Slovakia

  • Neurocrine Clinical Site

    Trenčín, Slovakia

  • Neurocrine Clinical Site

    Vranov nad Topľou, Slovakia

  • Neurocrine Clinical Site

    Gothenburg, Sweden

  • Neurocrine Clinical Site

    Halmstad, Sweden

  • Neurocrine Clinical Site

    Lund, Sweden

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.